NASDAQ:PMCB PharmaCyte Biotech (PMCB) Stock Price, News & Analysis → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Free PMCB Stock Alerts $2.16 -0.06 (-2.70%) (As of 02:03 PM ET) Add Compare Share Share Today's Range$2.15▼$2.1850-Day Range$1.95▼$2.5252-Week Range$1.92▼$3.23Volume1,371 shsAverage Volume24,454 shsMarket Capitalization$18.25 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get PharmaCyte Biotech alerts: Email Address Ad WealthPressThe system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! About PharmaCyte Biotech Stock (NASDAQ:PMCB)PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.Read More PMCB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PMCB Stock News HeadlinesDecember 18, 2023 | msn.comPMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024December 15, 2023 | finance.yahoo.comCompanies Like PharmaCyte Biotech (NASDAQ:PMCB) Are In A Position To Invest In GrowthApril 23, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.December 5, 2023 | morningstar.comPharmaCyte Biotech Inc PMCBNovember 15, 2023 | markets.businessinsider.comPharmaCyte Biotech Invests In Femasys - Quick FactsNovember 15, 2023 | finance.yahoo.comFemasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte BiotechJune 15, 2023 | msn.comPharmaCyte completes tender offer to purchase sharesJune 15, 2023 | finance.yahoo.comPharmaCyte Biotech Announces Final Results of Tender OfferApril 23, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.June 14, 2023 | bizjournals.comLos Angeles Biotech NewsMay 11, 2023 | finance.yahoo.comPharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per ShareApril 21, 2023 | nasdaq.comBiotech ETFs’ Performance Deserves A LookApril 12, 2023 | fortune.com300 biotech and pharma CEOs including the head of Pfizer call for a reversal of the abortion pill banFebruary 2, 2023 | msn.comA 45-year-old biotech CEO may have reduced his biological age by at least 5 years through a rigorous medical program that can cost up to $2 million a year, Bloomberg reportedFebruary 2, 2023 | finance.yahoo.comPharmaCyte Biotech to Implement Second $10-Million Share Repurchase PlanOctober 7, 2022 | seekingalpha.comPharmaCyte to evaluate opportunities; CEO steps downOctober 7, 2022 | markets.businessinsider.comPharmaCyte Names Joshua Silverman Interim CEO As CEO Kenneth Waggoner Steps DownAugust 15, 2022 | finance.yahoo.comPharmaCyte Biotech Reaches Cooperation Agreement with Iroquois CapitalJuly 28, 2022 | finance.yahoo.comIroquois Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech, Inc.July 21, 2022 | finance.yahoo.comPharmaCyte Biotech Commences First Phase of Two-Phase Pig StudyJuly 11, 2022 | finance.yahoo.comIROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORSJuly 11, 2022 | finance.yahoo.comPharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022July 5, 2022 | finance.yahoo.comPharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap CellsJune 23, 2022 | finance.yahoo.comIROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETINGJune 17, 2022 | stockhouse.comPharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital's Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder ValueJune 15, 2022 | finance.yahoo.comPharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder ValueJune 13, 2022 | finance.yahoo.comPharmaCyte Biotech to Attend 2022 BIO International Convention in San DiegoSee More Headlines Receive PMCB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PharmaCyte Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today4/23/2024Fiscal Year End4/30/2024Next Earnings (Estimated)7/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:PMCB CUSIPN/A CIK1157075 Webpharmacyte.com Phone917-595-2850Fax917-595-2851Employees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,320,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-9.69% Return on Assets-5.86% Debt Debt-to-Equity RatioN/A Current Ratio8.16 Quick Ratio8.16 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.33 per share Price / Book0.50Miscellaneous Outstanding Shares8,450,000Free Float7,836,000Market Cap$18.17 million OptionableOptionable Beta-0.18 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Joshua N. Silverman (Age 54)Interim CEO, President & Director Comp: $197.92kMr. Carlos A. Trujillo CPA (Age 66)CPA, Chief Financial Officer Comp: $380kDr. Jose L. Iglesias M.D. (Age 67)Consulting Chief Medical Officer Dr. Hans-Peter HammesMember of Medical & Scientific Advisory Board and ConsultantKey CompetitorsSurrozenNASDAQ:SRZNAptose BiosciencesNASDAQ:APTOEvaxion Biotech A/SNASDAQ:EVAXInhibikase TherapeuticsNYSE:IKTSenti BiosciencesNASDAQ:SNTIView All CompetitorsInstitutional OwnershipK2 Principal Fund L.P.Bought 46,132 shares on 2/14/2024Ownership: 3.534%View All Institutional Transactions PMCB Stock Analysis - Frequently Asked Questions How have PMCB shares performed in 2024? PharmaCyte Biotech's stock was trading at $2.16 at the start of the year. Since then, PMCB stock has increased by 0.0% and is now trading at $2.16. View the best growth stocks for 2024 here. Are investors shorting PharmaCyte Biotech? PharmaCyte Biotech saw a increase in short interest in March. As of March 31st, there was short interest totaling 45,700 shares, an increase of 501.3% from the March 15th total of 7,600 shares. Based on an average trading volume of 26,000 shares, the days-to-cover ratio is presently 1.8 days. Currently, 0.6% of the company's shares are short sold. View PharmaCyte Biotech's Short Interest. When is PharmaCyte Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 29th 2024. View our PMCB earnings forecast. How were PharmaCyte Biotech's earnings last quarter? PharmaCyte Biotech, Inc. (NASDAQ:PMCB) issued its earnings results on Monday, March, 18th. The company reported ($0.65) EPS for the quarter. How do I buy shares of PharmaCyte Biotech? Shares of PMCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PMCB) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersPentagon contract could send this $2 AI stock soaringBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmaCyte Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
